Cannabis Warning Label Regulations and Characteristics in US States with Medical and …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyDosingMental HealthPediatricsTHC Why This Matters Clinicians need standardized, evidence-based…
Alleviates Community Chronic Pain and Inflammation Accelerate
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainCBDResearchSafetyPolicyAnxietyMental Health Why This Matters Clinicians treating rheumatoid arthritis patients…
Guest columnist: Washington should ensure stable hemp market | State-Journal
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyHempCBDIndustrySafetyResearchDosing Why This Matters Clinicians prescribing or recommending hemp-derived…
Cannabinoid-Based Therapies Linked to Reduced Agitation in Alzheimer’s Patients, Meta …
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyCBDAgingMental HealthSafetyTHC Why This Matters Clinicians managing behavioral symptoms in…
Michigan universities can’t study dispensary pot on campus. MSU went mobile
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustryNeurologyMental HealthAnxiety Why This Matters Restrictions on campus-based cannabis research…
DEA Judge Issues Procedural Order for Marijuana Rescheduling Hearing
The DEA marijuana rescheduling procedural order sets the framework for the upcoming hearing on moving cannabis to Schedule III. This order establishes evidentiary standards that will influence federal cannabis research and clinical use. Clinicians should…
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthCBDSafetyDosingIndustryHemp Why This Matters Clinicians currently lack FDA-approved pharmacotherapy…
The CB2 receptor, key in resistance to trastuzumab – Demócrata
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchSafetyPolicyPainAnxietyMental Health Why This Matters Clinicians treating HER2-positive breast cancer…
Peter Vermeul’s Post
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchTHCCBDHempSafetyDosingNeurology Why This Matters Clinicians need to understand that cannabis effects depend on…
PleoPharma Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial
Cannabis withdrawal syndrome treatment is advancing with PleoPharma's Phase 3 trial of PP-01. This medication targets withdrawal symptoms that hinder recovery. The trial aims to improve treatment outcomes for cannabis use disorder.